HUAKANG BIOMED (08622.HK) Sets 27 March 2026 Board Meeting to Approve FY2025 Results and Discuss Final Dividend

Bulletin Express

Mar 17

Joyzyme Group Limited, trading as HUAKANG BIOMED (Stock Code: 08622), has announced that its board of directors will convene on 27 March 2026. The agenda includes:

• Reviewing and approving the audited consolidated financial results for the year ended 31 December 2025. • Considering the declaration and payment of a final dividend, if any. • Addressing other routine corporate matters.

The board currently consists of four Executive Directors—Ms. Zhang Yujing, Dr. Zhou Xunyong, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael; two Non-executive Directors—Dr. Bu Su and Dr. Xu Ming; and three Independent Non-executive Directors—Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Mr. Tsui Wing Tak.

The company confirms that all information in the announcement is accurate and complete to the best of the directors’ knowledge. The notice will remain available on the Hong Kong Stock Exchange website and the company’s website for at least seven days from the publication date of 17 March 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1192476791"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192476791\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192476791?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192476791","market":"hk","top_or_hot":-1,"title":"HUAKANG BIOMED (08622.HK) Sets 27 March 2026 Board Meeting to Approve FY2025 Results and Discuss Final Dividend","media":"Bulletin Express","content":"<p>Joyzyme Group Limited, trading as HUAKANG BIOMED (Stock Code: 08622), has announced that its board of directors will convene on 27 March 2026. The agenda includes:</p>\n<p>• Reviewing and approving the audited consolidated financial results for the year ended 31 December 2025.  \n• Considering the declaration and payment of a final dividend, if any.  \n• Addressing other routine corporate matters.</p>\n<p>The board currently consists of four Executive Directors—Ms. Zhang Yujing, Dr. Zhou Xunyong, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael; two Non-executive Directors—Dr. Bu Su and Dr. Xu Ming; and three Independent Non-executive Directors—Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Mr. Tsui Wing Tak.</p>\n<p>The company confirms that all information in the announcement is accurate and complete to the best of the directors’ knowledge. The notice will remain available on the Hong Kong Stock Exchange website and the company’s website for at least seven days from the publication date of 17 March 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUAKANG BIOMED (08622.HK) Sets 27 March 2026 Board Meeting to Approve FY2025 Results and Discuss Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUAKANG BIOMED (08622.HK) Sets 27 March 2026 Board Meeting to Approve FY2025 Results and Discuss Final Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-17 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Joyzyme Group Limited, trading as HUAKANG BIOMED (Stock Code: 08622), has announced that its board of directors will convene on 27 March 2026. The agenda includes:</p>\n<p>• Reviewing and approving the audited consolidated financial results for the year ended 31 December 2025.  \n• Considering the declaration and payment of a final dividend, if any.  \n• Addressing other routine corporate matters.</p>\n<p>The board currently consists of four Executive Directors—Ms. Zhang Yujing, Dr. Zhou Xunyong, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael; two Non-executive Directors—Dr. Bu Su and Dr. Xu Ming; and three Independent Non-executive Directors—Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Mr. Tsui Wing Tak.</p>\n<p>The company confirms that all information in the announcement is accurate and complete to the best of the directors’ knowledge. The notice will remain available on the Hong Kong Stock Exchange website and the company’s website for at least seven days from the publication date of 17 March 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"08622","symbol_name":"华康生物医学","start_time":0,"source_url":"","article_id":"1192476791","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192476791","pubTimestamp":1773745387,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Joyzyme Group Limited, trading as HUAKANG BIOMED (Stock Code: 08622), has announced that its board of directors will convene on 27 March 2026. The agenda includes: • Reviewing and approving the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"08622":"华康生物医学"},"translate_title":"华康生物医药(08622.HK)定于2026年3月27日召开董事会批准2025财年业绩并讨论末期股息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"08622":1},"content_text":"Joyzyme Group Limited, trading as HUAKANG BIOMED (Stock Code: 08622), has announced that its board of directors will convene on 27 March 2026. The agenda includes:\n• Reviewing and approving the audited consolidated financial results for the year ended 31 December 2025.  \n• Considering the declaration and payment of a final dividend, if any.  \n• Addressing other routine corporate matters.\nThe board currently consists of four Executive Directors—Ms. Zhang Yujing, Dr. Zhou Xunyong, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael; two Non-executive Directors—Dr. Bu Su and Dr. Xu Ming; and three Independent Non-executive Directors—Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Mr. Tsui Wing Tak.\nThe company confirms that all information in the announcement is accurate and complete to the best of the directors’ knowledge. The notice will remain available on the Hong Kong Stock Exchange website and the company’s website for at least seven days from the publication date of 17 March 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}